It's hoped the FDA will approve an artificial pancreas in 2017. The device is expected to transform treatment of type 1 diabetes.
In an interview with CNBC, the NIH director said people may be "a little cynical" because of cancer's casualty rate, but researchers 'had its number.'
Mount Sinai Hospital's CEO told CNBC that while Obamacare survived a repeal attempt, it's locked in a tough game of numbers.
Peloton Cycle CEO John Foley explains how the company behind indoor cycling technology is experiencing massive growth.
New advances provide new hope for prosthetics, including an accurate sense of touch and robotic limbs developed at a fraction of the cost.
Before testing your own genome, it helps to realize it can raise more questions than it answers.
A $199 service from health company 23andMe gives individuals data from ancestry to risks of carrying a genetic condition.
Personalized medicine is more costly than traditional treatment, which worries insurers. But these drugs can improve outcomes for patients.
Surgeons use 3-D printed replica of patients' brains to improve surgery performance.
About 1 in 5 Medicare dollars is spent on this disease that affects over 5 million Americans. Yet not enough is being done to find a cure.
Some of those generic pills you buy at the drug store could change ownership Friday.
Bone replacements, human tissue and prosthetics are being created by 3-D bioprinters. The science will soon be used to customize drugs.
Lars Rebien Sørensen, CEO of Novo Nordisk, discusses his company's earnings guidance and strong half year growth, as well as its strategy in China.
The federal government says health care facilities should stop using Hospira's Symbiq medication infusion pump because its vulnerable to hacking.
The CEO of Medtronic talks new FDA approval and how to improve the health-care system.
Mount Sinai's CEO sees a "death spiral" could occur if the Supreme Court rules against the health insurance subsidies in Obamacare.
Bad news has been a boon for Malaysia's rubber glove makers, with the ringgit's drop and South Korea's MERS outbreak likely to provide a twin boost.
There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.
Cathrin Petty, co-head of EMEA healthcare at JP Morgan, says the U.K. has the capacity to be a successful market for life sciences, and the year ahead for healthcare IPOs looks strong.
George Freeman MP, minister of life sciences in the U.K., says there's been a "resurgence" for life sciences and healthcare investment.